Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice

Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice

BackgroundThe intestinal microbiota disorder gradually aggravates during the progression of diabetes. Dapagliflozin (DAPA) can improve diabetes and diabetic kidney disease(DKD). However, whether the gut microbiota plays a role in the protection of DAPA for DKD remains unclear.MethodsTo investigate t...

Full description

Bibliographic Details
Main Authors: Jiajia Wu, Yan Chen, Huinan Yang, Leyi Gu, Zhaohui Ni, Shan Mou, Jianxiao Shen, Xiajing Che
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
dapagliflozin
diabetes kidney disease (DKD)
Muribaculaceae
Lactobacillus
bile acid
therapeutic targets
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1026040/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1026040/full

Similar Items